| Literature DB >> 17825095 |
Masja Straetemans1, Udo Buchholz, Sabine Reiter, Walter Haas, Gérard Krause.
Abstract
BACKGROUND: Although there is rapid progress in vaccine research regarding influenza pandemic vaccines it is expected that pandemic influenza vaccine production can only start once the pandemic virus has been recognized. Therefore, pandemic vaccine capacity will be limited at least during the first phase of an influenza pandemic, requiring vaccine prioritization strategies. WHO recommends developing preliminary priorities for pandemic vaccine use. The goal of this review is to provide a thorough overview of pandemic vaccine prioritization concepts in the 27 European Union (EU) member states and the four non-EU countries of the Global Health Security Action Group.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17825095 PMCID: PMC2048949 DOI: 10.1186/1471-2458-7-236
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Establishment of Vaccine Priority Groups in EUA and GSHAGB countries
| ATA | yes | yes | yes | 3 | no1a | no | yes1b | yes | yes | yes | yes | no | no |
| BEA | yes | yes | yes | discussion | not applicable | not applicable | no | unknown | |||||
| BGA | yes | yes | no | 3 | yes | yes | noI | yes3 | yes | yes | yes | yes | no |
| CAB,2 | yes | yes | no | 5H | yes | yes | noI | yes | yes | yes | yes | yes | no |
| CYA | noG | yes | no | 5H | unknown | yes | yes | yes | partly4 | yes | yes | yes | no |
| CZA, | yes | yes5 | no | 3 | yes | unknown | unknown | unknown | yes | yes | yes | no | no |
| DKA,6 | yes | yes | yes | 7H | yes | yes, 2 groups6 | no | yes | yes | yes | yes | yesJ | no |
| EEA | yes | yes | no | 3 | yes | yes | noI | yes | yes | yes | yes | partlyK | yes |
| FIA,7 | noG | yes | no | 17 | unknown | yes, 1 group7 | yes | yes | yes7 | no7 | no7 | no | no |
| FRA,B,8 | yes | yes | yes | 3 | no | no | no | unknown | yes | yes | yes | no | no |
| DEA,B | yes | yes | yes | 29a | no9b | yes | no | yes | yes | yes | no | no | no |
| GRA,10 | yes | yes | no | 510 | unknown | discussion10 | yes | unknown | yes10 | yes10 | yes10 | no | yes10 |
| HUA | yes | yes | no | 3 | no | yes | no | yes | yes | yes | yes | no | no |
| IEA | yes | yes | no | 7H | yes | yes | noI | yes | yes | yes | yes | yesJ | yes |
| ITA,B | yes | yes | no | 6H | yes | yes | no | yes | yes | yes | yes | yes | yes |
| JPB,11 | yes | yes | yes | 6H | discussion | discussion | no | yes | yes | yes | yes | yes | yes |
| LVA,12 | noG | yes | no | 012 | not applicable | not applicable | unknown | unknown | |||||
| LTA,13 | yes | yes | no | 4 | yes | discussion | no | yes | yes | yes | yes | no | no |
| LUA | yes | no | yes | 0 | not applicable | not applicable | unknown | unknown | |||||
| MTA | no14a | yes | no | 8H14b | no | yes | no | yes | yes | yes | yes | yes | yes |
| MXB,15 | noG | yes | no | 0 | not applicable | not applicable | yes | unknown | |||||
| POA,16 | yes | yes | no | 2 | yes | no | unknown | unknown | yes | yes | yes | partlyK | no |
| PTA | noG | yes | no | discussion | unknown | discussion | yes | yes | |||||
| ROA | noG | yes | no | 5 | yes | yes | yes | unknown | yes | yes | yes | partlyK | yes |
| SKA | yes | yes | no | 4 | yes | no | no | unknown | yes | yes | yes | no | yes |
| SIA | noG | yes | no | 4 | no | yes | noI | unknown | yes | yes | yes | partlyK | no |
| ESA | yes | yes | no | 4H | discussion | yes | no | discussion | yes | yes | yes | yes | no |
| SEA | yes | yes | no | 7H | no | no | yes | yes | yes | yes | yes | yes | yes |
| NLA | yes | yes | yes | 4H | yes | yes | no | yes | yes | no | yes | yes | no |
| UKA,B,17 | yes | yes | no | 7H | yes | yes | yes | yes | yes | yes | yes | yesJ | yes |
| USB,18 | yes | no | yes | 4H | yes | yes | yes | yes | yes | yes | yes | yes | yes |
A Member State of European Union (EU); B Member of Global Health Security Action Group (GSHAG); C 'yes'indicates that either National Pandemic Plan specifically reports the aim to vaccinate whole population and/or National Pandemic Plan includes 'healthy adults and children' as one of the vaccine priority group(s) and/or country representatives specifically reported this information; 'discussion' indicates country representative specifically reported that vaccination policy is still under discussion, 'unknown' indicates that this item is not specifically reported; D The issue of prioritisation arises only in the situation of vaccine shortage or when vaccines become available over time; E 'yes refers to those countries either specifying 'healthy adults and children' as vaccine priority group(s) and those countries reporting 'offer to all' as vaccine priority group; F Vaccine priority groups that could not be categorized in the four most common vaccine priority groups as described in this table; G National Pandemic Plan available in public domain in language other than English, Danish, Dutch, French, German or Swedish; H Including a category referring to vaccination of whole population; I Ethics considerations will be involved in the future; J Included under the vaccine priority group 'offer to all'; K Countries have included 'children' under 'high risk individuals'
1a (AT) National Pandemic Plan serves as a framework to guide each of the nine states to develop specific plan including vaccine priority subgroups; 1b No specific ethical committee involved but ethical considerations have been involved;
2 (CA) Advancements in knowledge and technology are currently being considered by the Pandemic Vaccine Working group and may result in the revision of vaccine priority groups in updated Pandemic Plan in 2007
3 (BG) Specified in draft national influenza preparedness plan of Bulgaria as "aim is to cover gradually the maximum part of the population";
4 (CY) Specified as people working in the Health Sector involved with the distribution of vaccines and antivirals;
5 (CZ) Information received by email is from the unpublished National Pandemic Plan of the Czech Republic 2006;
6 (DK) Prioritisation of vaccine strategies will be decided during the course of a pandemic, the information in the table reflects the discussion paper in the pandemic plan;
7 (FI) Irrespective of the virus one vaccine priority group is determined in advance;
8 (FR) Working groups are updating strategies using pre-pandemic modelling but also accurate survey of the population and age-groups most affected by virus, associated with models of progressive availability of the vaccine in relation with the kinetics of a pandemic will determine the vaccine priority groups;
9a (DE) Two main vaccine priority groups have been determined, discussion related to criteria of establishing further vaccine priority groups are under discussion 9b National Plan serves as a framework to guide each of the 16 states to develop specific plan including vaccine priority subgroups.
10 (GR) Is in the process of discussing and further refining vaccine priority groups, the information in the table includes "suggested priority groups" as published in National Pandemic Plan;
11 (JP) Prioritisation is under discussion and the table includes information in draft guidelines available for public discussion and comments;
12 (LV) Influenza Pandemic Preparedness Plan of Latvia will be updated in 2007;
13 (LT) Vaccine priority groups will be revised in the "near future" [as of October 26th 2006];
14a (MT) National Influenza Pandemic Standing Committee has decided on vaccine priority groups and currently the plan prepared by this committee is being approved and amended by the Director General; 14b Seven of eight reported vaccine priority groups have been categorized under four main categories included in this table;
15 (MX) Current National Preparedness and Response Plans does not include a scenario in which pandemic vaccine is available; this aspect may be updated as information on vaccine production and availability becomes available.
16 (PL) More specific and detailed strategy under discussion;
17 (UK) Plan is currently under revision, including more modelling of immunisation strategies;
18 (US) Revision of order prioritisation of tiers is expected in spring 2007.
Common reported subgroups within three main vaccine priority groups as listed in National Influenza Pandemic Plans A
| . | . | . | . | . | . | . | X | . | . | . | . | XF | |||
| Clinical laboratories, pharmacies | X | X | X | . | X | . | . | . | . | X | . | X | . | . | 6 (43%) |
| Paramedics, emergency services | X | X | X | X | . | X | X | . | X | X | . | X | X | . | 10 (71%) |
| Residential care homes for elderly | . | X | . | . | . | X | . | . | . | . | . | . | X | . | 3 (21%) |
| Social institutions (e.g. day care, "elderly houses") | X | . | X | X | . | . | . | . | . | . | X | . | . | . | 4 (29%) |
| Public health agencies/authorities | X | X | X | . | X | . | X | . | . | X | . | . | . | . | 6 (43%) |
| Long term health care facilities | . | X | X | . | . | . | X | . | X | . | X | X | . | . | 6 (43%) |
| Out-patient health care facilities | X | X | X | X | . | . | X | . | . | X | . | X | . | . | 7 (50%) |
| In-patient health care facilities | X | X | X | X | . | X | X | . | X | X | . | X | X | . | 10 (71%) |
| X | X | XC | XD | . | XE | . | . | X | : | X | . | XE | X | ||
| Police | X | X | X | . | X | X | X | . | X | X | X | . | X | . | 10 (71%) |
| Armed forces | X | X | X | . | X | X | X | . | X | X | X | . | X | . | 10 (71%) |
| Fire fighters | X | X | X | . | . | X | X | . | X | X | X | . | X | . | 10 (71%) |
| Government | X | X | X | . | . | . | . | . | . | X | X | . | . | X | 6 (43%) |
| Emergency response decision makers | X | X | . | . | X | . | X | X | . | . | . | . | . | X | 6 (43%) |
| Border guards and custom officers | X | . | . | . | X | . | X | . | X | X | . | . | . | . | 5 (36%) |
| Defined national authorities | X | X | . | 2 (14%) | |||||||||||
| XC | . | . | . | . | X | XE | . | . | . | . | XD | ||||
| Utility workers (e.g. power, water, sewage system) | X | X | X | . | X | X | X | X | . | X | X | . | X | X | 11 (79%) |
| Funeral services/mortuary personnel | X | X | . | . | . | X | . | . | . | X | . | . | X | X | 6 (43%) |
| Transport (e.g. fuel, water, food, medical supplies) | X | X | X | . | . | . | X | . | X | X | X | . | X | 8 (57%) | |
| Groups identified in pandemic as being at increased risk for complications | X | X | . | X | . | X | . | . | . | . | . | X | X | . | 6 (43%) |
| Sub-groups similar to those where vaccination is recommended during seasonal influenza | X | X | X | . | X | X | X | X | X | X | X | X | X | X | 13 (93%) |
| Pregnant women | . | X | . | . | X | . | . | . | X | . | . | . | . | X | 4 (29%) |
| Pregnant women in the third trimester | . | . | . | . | . | X | . | X | . | . | . | X | X | . | 4 (29%) |
| Children 6 to 23 months | . | X | . | . | . | X | X | . | . | X | . | . | . | X | 4 (29%) |
| Children and youth 6 months to 18 years | . | . | . | . | X | . | . | . | X | . | . | . | . | . | 2 (14%) |
A Table includes countries which listed subgroups in their published National Pandemic Influenza Plans that either met the language criteria (see Methods) or provided detailed information on request; B Due to countries variation in the terminology among countries overlaps between subgroups may exist. Table includes subgroups if categorized by countries as belonging to one of the main groups; C National Pandemic Influenza Plan reports a comprehensive list of subgroups which is not completely summarized in this table; D National Pandemic Influenza Plan reports a comprehensive list of groups which could be considered and is not summarized in this table. "Decisions on priority groups will be made when the characteristics of the new pandemic virus is known and according to ongoing work on vulnerability in specific key sectors"; E Unmarked subgroups are not necessarily excluded because the National Pandemic Influenza Plan only reports a few examples; F No further specification.
List of vaccine priority groups other than health care workers, essential service providers, high risk individuals and healthy adults/children
| Long term care facility residentsA | X | 1 (9%) | ||||||||||
| Individuals living in "closed communities" ( | . | X1 | . | . | . | . | . | . | . | 1 (9%) | ||
| Individuals in crowding area ( | . | X1 | . | . | . | . | . | . | . | . | . | 1 (9%) |
| Staff of workplaces where many people gather ( | . | . | . | . | . | . | . | X | . | . | . | 1 (9%) |
| "Selected age groups, depending on national and/or WHO advice"B | . | . | X | . | X | . | . | . | X | . | 3 (27%) | |
| Selected industries (e.g. pharmaceuticals)C | . | . | X | . | . | . | . | . | X | . | 2 (18%) | |
| Pandemic vaccine manufacturersD | . | . | . | X2 | . | . | X4 | . | . | . | X5 | 3 (27%) |
| Household contacts of immunocompromised personsE | . | . | . | . | . | . | . | X | . | . | X | 2 (18%) |
| Household contacts of high-risk patients | X | . | . | . | . | . | . | . | X | . | . | 2 (18%) |
| Household contacts of children | . | . | . | . | . | . | . | . | . | . | X | 1 (9%) |
| Seniors | X3 | 1 (9%) |
A Specified as additional vaccine priority group to the "high risk individuals"; while in other countries these individuals may be included in seasonal vaccination group; B Vaccination policy might be revised in the event of one or more age groups being more severely affected in a pandemic; C Reported as separate vaccine priority group; while in other countries these individuals might have been included, but had not been listed, under the "essential workers"; D Countries have specifically reported this (sub) group while in other countries these might have been included, but had not been listed, under "essential workers"; E This category also includes "family members of persons with impaired immunity" (SK); 1 Currently in the process of discussing and refining further priority groups, information in the table includes "suggested" priority groups as published in the National Pandemic Plan; 2 Not listed in National Pandemic Plan, but updated information received from country representative; 3 Reported as separate vaccine priority groups in draft guidelines; 4 Specified as separate (1 of 6) vaccine priority group; 5 Specified as 'subtier' belonging to one of four 'tiers' and includes also antiviral manufacturers
Ranking of vaccine priority groups A
| Countries | |||||
| BGB | Health care workers Essential service providers | High risk individuals | Healthy adults and children | ||
| CA | Health care workers | Essential service providers | High risk individuals | Healthy adults | Children |
| CY | Health care workers involved with vaccines and antiviral distribution | Essential service providers | High risk individuals | Healthy adultsC | Individuals aged 2–18 yrsC |
| DKD | High risk individuals | - | - | - | |
| EEE | Health care workers | Essential service providers | High risk individuals | - | - |
| FIF | Health care workers | - | - | - | - |
| DE | Health care workers | Essential service providers | - | - | - |
| HU | Health care workers | Essential service providers | |||
| IE | Health care workers | Essential service providers | High risk individuals | Individuals aged > 65 yrs. | 5) Selected industries |
| IT | Health care workers | Essential service providers | High risk individuals | Healthy individuals aged 2–18 yrs. | Healthy adults |
| MT | Health care workers Essential service providers | Specific age groups with high complication risk | Individuals aged > 65 yrs with chronic diseasesG | Individuals aged 2–64 yrs. with chronic diseasesG | 5)Individuals > 65 years without chronic disease |
| RO | Health care workers | Vaccine manufacturers and distribution staff | Essential service providers | Long term care facilities residents | High risk individuals |
| SI | Health care workers | Workers involved in pandemic control | High risk individuals | - | - |
| ES | Health care workers | Essential service providers | High risk individuals | Healthy adults and children | |
| NLH | "Highest risk" individuals | Health care workers | Specific Pandemic Risk groups | Healthy adults and children | - |
| UK | Health care workers | Essential service providers | High risk individuals | Individuals aged > 65 yrs. | 5) Selected industries |
| USI | Vaccine and antiviral manufacturers Health care workers (Tier 1a) | High risk individuals (Tier 1b) | Pregnant woman, household contacts of severely immunocompromised persons, household contacts of children (Tier 1c) | Public health emergency response, Key governmental leaders (Tier 1d) | 5) Healthy individuals aged ≥ 65; individuals aged 6 months to 64 yrs. with 1 high-risk condition; healthy infants aged 6–23 months (Tier 2a) |
A The issue of prioritisation arises only in the situation of absolute or temporal vaccine shortage (or need for time wise stratification due to production time-frame); B A final decision regarding priorities will be taken under the conditions of the pandemic; C In view of the large numbers of persons among healthy adults and children a decision to vaccinate them will depend on the availability of vaccines, in view of the big numbers of persons covered by these groups; D Includes only the two vaccine priority groups who are determined as for prioritisation in advance: decisions on further prioritisation by one of five vaccination strategies as reported in the National Pandemic Influenza Preparedness Plan will be made during the course of the pandemic; E Estonian mass vaccination policy foresees four immunization strategies of which implementation depends on vaccine availability; the table includes the prioritization y in two of four strategies assuming limited vaccine; F Includes the one vaccine priority group determined in advance; further decisions will be made when more information about the virus is available; G In the case that all age groups are affected similarly then these groups will be prioritised (as decided by Malta's National Influenza Pandemic Standing committee and currently being approved and amended by the Director General); H The Health Council Committee defined four groups of people that, on medical grounds are most in need of vaccination. "Group 1" will be vaccinated first; in this table this group is depicted as 'highest complication individuals'; the category "Specific Pandemic Risk Groups" probably shows overlap with the "Group 2–4" as defined by the Health Council Committee; healthy adults and children will be vaccinated when enough vaccine is available 10; I Vaccination priority groups are categorised into 4 tiers including subtiers which will be vaccinated with increasing availability of vaccine. Description in this table is limited to tear 1–2. Currently discussion is ongoing to update the ranking of vaccine priority groups.
Overview of rationales considered in EU and GSHAG countries to define vaccine priority groups A
| AT | BG | CA | CY | CZ | DK | EE | FI | FR | DE | GR | HU | IE | IT | JP | LT | MT | PL | RO | SK | SI | ES | SE | NL | UK | US | |
| X | XB | X | . | . | XE | . | . | . | X | . | . | X | . | . | . | . | . | X | . | X | X | . | . | X | . | |
| To save years of life | . | . | . | . | . | . | . | XF | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |
| To prevent illness in the general population | X | . | X | . | . | XE | . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | X | X | |
| - in individuals most vulnerable to severe illness | . | X | X | . | . | XE | . | . | X | . | . | . | . | . | XI | X | . | . | . | . | . | X | X | X | X | |
| - in age groups most vulnerable to severe illness | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | . | . | . | . | . | X | . | . | . | |
| - in health care workers at increased exposure risk* | . | . | X | . | . | XE | X | X | X | X | X | X | . | x | . | . | . | . | X | . | . | . | X | X | X | X |
| - by preventing or minimising the spread of infection | . | X | ||||||||||||||||||||||||
| . | . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | . | . | . | X | |||
| . | . | . | . | . | XE | . | . | . | X | . | . | . | . | . | . | . | . | . | . | . | . | X | . | X | ||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | ||
| X | X | . | . | . | . | . | . | . | X | . | . | . | XG | . | . | . | . | . | . | . | X | . | . | X | X | |
| By maintaining the major work force | . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | ||
| By maintaining the essential community services | . | X | X | X | . | XE | X | . | X | X | X | X | X | . | X | X | . | X | . | X | . | X | X | X | X | |
| . | ||||||||||||||||||||||||||
| . | . | . | XC | . | . | X | . | X. | . | . | . | . | . | . | . | . | . | . | X | . | . | . | . | X | ||
| . | . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | . | . | . | X | . | . | X | ||
| . | . | X | . | . | XE | X | X | X | X | X | . | XG | . | . | X | . | X | . | . | . | X | X | X | X | ||
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | X | . | . | . | . | . | . | . | . | . | |||
| . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |
| . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |
| X | X | X | X | D | XE | X | X | X | X | X | X | X | X | H | X | X | H | X | J | X | X | X | X | X | X | |
| X | X | X | . | . | XE | X | X | X | X | X | X | X | X | . | X | X | . | X | . | X | X | X | X | X | X | |
| X | X | X | X | . | XE | X | X | X | X | X | X | X | X | . | X | X | . | X | . | X | X | X | X | X | X | |
| . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | |
| . | X | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | . |
* To provide a complete overview and deal with different terminology of countries in specifying this rationale we have marked the rationale in both categories for each country specifying this rationale;
A Level of detailed specification of rationales varied between the countries, as a result rationales in this table may overlap; B In more detail specified as "to reduce complications, necessity of hospitalizations and lethality"; C Specified followed: 'Covering those who are going to be actively involved in mastering a possible pandemic'; D National Influenza Pandemic Plan includes the following general statement: 'Vaccine Priority groups have been established according to clear, medical, social and economic reasons'; E National Influenza Pandemic Plan describes 5 strategies which are the basis for the different rationales to decide which vaccine groups will be prioritized; during the course of the pandemic decision will be made which strategies to follow; F Number of potential life years saved will be the most important determining factor for prioritization; G National Influenza Plan does not contain specific rationales, but rationales which set priorities as represented in this table were given through personal communication; H Rationales are under discussion; I Specified as individuals at highest risk of influenza; J National Influenza Pandemic plan does not contain specification of rationales for priority setting; personal communication reveals that the main principle is "to involve groups in the highest risk of infection, complication and death and groups in the population that are important for maintaining the public life".